Lack of pharmacokinetic interaction between St. John's wort and prednisone

Annals of Pharmacotherapy

Volumn 41, Issue 11, 2007, Pages 1819-1824

  Bell, Edward C ^a   Ravis, William R ^b   Hui, Min Chan ^b   Lin, Yuh Jing ^b  

^a TEXAS SOUTHERN UNIVERSITY   (United States)

^b AUBURN UNIVERSITY   (United States)

Author keywords

Cytochrome; Metabolism; Prednisolone; Prednisone; St. John's wort

Indexed keywords

CYTOCHROME P450 3A4; GLYCOPROTEIN P; HYPERICUM PERFORATUM EXTRACT; PREDNISONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NORMAL HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DIETARY SUPPLEMENTS; DRUG ADMINISTRATION SCHEDULE; GLUCOCORTICOIDS; HERB-DRUG INTERACTIONS; HUMANS; HYPERICUM; MALE; PLANT PREPARATIONS; PLANTS, MEDICINAL; PREDNISOLONE; PREDNISONE;

EID: 35748932937     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K316     Document Type: Article

References (30)

1. Timbo BB, Ross MP, McCarthy PV, Lin CT. Dietary supplements in a national survey: prevalence of use and reports of adverse events. J Am Diet Assoc 2006;106:1966-74.
2. Woelk H. Comparison of St. John's wort and Imipramine for treating depression: randomised controlled trial. BMJ 2000;321:536-9.
3. Wheatley D. LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients - a controlled 6-week clinical trial. Pharmacopsychiatry 1997;30(suppl 2):77-80.
4. Schader E. Equivalence of St. John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild to moderate depression. Int Clin Psychopharmacol 2000;15:61-88.
5. Harrer G, Hubner WD, Podzuweit H. Effectiveness and tolerance of the hypericum extract LI160 compared to maprotiline: a multicenter double-blind study. J Geriatr Psychiatry Neurol 1994;7(suppl 1):S24-8.
6. Fava M, Alpert J, Nierenberg AA, et al. A double-blind, randomized trial of St. John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol 2005;5:441-7.
7. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St. John's wort) in major depressive disorder: a randomized controlled trial. JAMA 2002;287:1807-14.
8. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A:ontogeny and drug disposition. Clin Pharmacokinet 1999;37:485-505.
9. Moore LB, Goodwin B, Jones SA, et al. St. John's wort induces drug metabolism through the activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000;97:7500-2.
10. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000;294:88-95.
11. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko U, Hall SD. The effects of St. John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001;70:305-10. DOI 10.1016/S0009-9236(01)00127-8
12. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St. John's wort. Lancet 2000;355:547-8.
13. Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W. Lack of effect of St. John's wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 2000;68:605-12.
14. Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zepelin HH. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St. John's wort extract. Planta Med 2005;71:331-7.
15. Mueller SC, Majcher-Peszynska J, Uehleke B, et al. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol 2006;62:29-36.
16. Rose JQ, Yurchak AM, Jusko WJ. Dose dependent pharmacokinetics of prednisone and prednisolone in man. J Pharmacokinet Biopharm 1981;9: 389-417.
17. Waxman DJ, Attisano C, Guengerich FP, Lapenson DP. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 1988;263:424-36.
18. Murphy PA. St. John's wort and oral contraceptives: reasons for concern? J Midwifery Womens Health 2002;47:447-50.
19. Hall SD, Wang Z, Huang SM, et al. The interaction between St. John's wort and an oral contraceptive. Clin Pharmacol Ther 2003;74:525-35. DOI 10.1016/j.clpt.2003.08.009
20. Jusko WJ, Pyszczynski NA, Bushway MS, D'Ambrosio R, Mis SM. Fifteen years of operation of a high-performance liquid chromatographic assay for prednisolone, Cortisol and prednisone in plasma. J Chromatogr B Biomed Appl 1994;658:47-54.
21. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15:657-80.
22. Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernas H. St. John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther 2004;75:298-309. DOI 10.1016/j.clpt.2003.12.012
23. Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K. Different effects of St. John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001;70:540-5. DOI 10.1016/S0009-9236(01)64092- X
24. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P4503A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995;13:129-34.
25. Mai I, Bauer S, Perloff ES, Johne A, Uehleke B, Frank B. Hyperforin content determines the magnitude of the St. John's wort-cyclosporine drug interaction. Clin Pharmacol Ther 2004;76:330-40. DOI 10.1016/j.clpt.2004.07.004
26. Johne A, Schmider J, Brockmoller J, et al. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum). J Clin Psychopharmacol 2002; 22:46-54.
27. Wang LS, Zhou G, Zhu B, et al. St. John's wort induces both cytochrome P450 3 A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 2004;75:191-7. DOI 10.1016/j.clpt.2003.09.014
28. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St. John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500-4.
29. Wolbold R, Klein K, Burk O, et al. Sex is major determinant of CYP3A4 expression in human liver. Hepatology 2003;38:978-88.
30. Paine MF, Ludington SS, Chen ML, Stewart PW, Huang SM, Watkins PB. Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression? Drug Metab Dispos 2005;33:426-33.